SEMA4D and pancreatic endocrine carcinoma: According to Zuazo-Gaztelu and colleagues, SEMA4D expression increased with tumor progression in pancreatic neuroendocrine cancer, and anti-SEMA4D antibody reduces tumor growth and tends to lengthen mouse lifespan [37].